A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
Trial details
- Registry ID
- NCT05306574
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as RC18; RC18-L
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)NCT05306574 | Vor Biopharma | Phase 3 | Terminated | 2025-01-06Actual |
| Chinese Adults With Kidney DiseaseNCT07522099 | ADRX | Phase 2 | Recruiting | 2028-07-10Estimated |
| Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseNCT07404865 | Vor Biopharma | Phase 3 | Recruiting | 2028-12Estimated |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)NCT06456580 | Vor Biopharma | Phase 3 | Active not recruiting | 2027-03Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |